Fanglin Hu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Fanglin Hu has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Fuhua Fu
Longping Branch, College of Biology, Hunan University, Changsha 410125, China
1 shared publication - Jiaxu Chen
Hunan Institute of Agricultural Product Processing and Quality Safety, Dongting Laboratory, Hunan Academy of Agricultural Sciences, Changsha 410125, China
1 shared publication - Jiwei Mao
Department of Life Sciences, Chalmers University of Technology, SE412 96 Gothenburg, Sweden
1 shared publication - Juan Liu
Hunan Institute of Agricultural Product Processing and Quality Safety, Dongting Laboratory, Hunan Academy of Agricultural Sciences, Changsha 410125, China
1 shared publication - Liusha Fan
Longping Branch, College of Biology, Hunan University, Changsha 410125, China
1 shared publication - Qiyuan Lu
Longping Branch, College of Biology, Hunan University, Changsha 410125, China
1 shared publication
Latest Publications
- Open Access
- 22 October 2025
- Published by MDPI AG in Microorganisms
- Vol. 13 (11) , 2422
Metabolic Engineering of Yeasts for the Production of the Triterpene Squalene: Current Status and Future Prospective
Squalene, a linear triterpene compound characterized by its distinctive isoprenoid backbone with six transisoprene units, is widely used in the medicinal, nutraceutical, and cosmetic industries. The escalating global demand for squalene, coupled with growing ethical concerns over shark-derived sources and the inherent limitations of plant extraction (low yield) and chemical synthesis (environmental burden), has propelled microbial biosynthesis as a sustainable alternative. While substantial progress has been made in elucidating the mevalonate pathway and regulatory mechanisms of squalene biosynthesis, achieving industrially viable titers through microbial platforms remains an unresolved challenge. This review systematically summarizes recent advances in squalene biosynthesis using yeast chassis, with a focus on metabolic engineering strategies implemented in Saccharomyces cerevisiae and Yarrowia lipolytica. Furthermore, we elaborated on how squalene yields a diverse array of downstream derivatives through intricate enzymatic reactions. These derivatives—including triterpenoid saponins, triterpenoid acids, and steroids—exhibit significant applications in the pharmaceutical, nutraceutical, and cosmetic sectors. By integrating systems metabolic engineering with emerging synthetic biology tools, this work provides a roadmap for advancing strain engineering toward economically feasible squalene biomanufacturing.
- 22 October 2025
- Published by MDPI AG in Microorganisms
- Vol. 13 (11) , 2422
Open AccessMetabolic Engineering of Yeasts for the Production of the Triterpene Squalene: Current Status and Future Prospective
Squalene, a linear triterpene compound characterized by its distinctive isoprenoid backbone with six transisoprene units, is widely used in the medicinal, nutraceutical, and cosmetic industries. The escalating global demand for squalene, coupled with growing ethical concerns over shark-derived sources and the inherent limitations of plant extraction (low yield) and chemical synthesis (environmental burden), has propelled microbial biosynthesis as a sustainable alternative. While substantial progress has been made in elucidating the mevalonate pathway and regulatory mechanisms of squalene biosynthesis, achieving industrially viable titers through microbial platforms remains an unresolved challenge. This review systematically summarizes recent advances in squalene biosynthesis using yeast chassis, with a focus on metabolic engineering strategies implemented in Saccharomyces cerevisiae and Yarrowia lipolytica. Furthermore, we elaborated on how squalene yields a diverse array of downstream derivatives through intricate enzymatic reactions. These derivatives—including triterpenoid saponins, triterpenoid acids, and steroids—exhibit significant applications in the pharmaceutical, nutraceutical, and cosmetic sectors. By integrating systems metabolic engineering with emerging synthetic biology tools, this work provides a roadmap for advancing strain engineering toward economically feasible squalene biomanufacturing.